Who are denovoSkin(TM)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Leukocyte rich platelet rich plasma, Regenerative tissue matrix, Platelet Rich Plasma (PRP), AMNIOGEN, Reactivation Mismatch, Low-dose PRP.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/denovoskin-tm.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

denovoSkin(TM) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

denovoSkin(TM) (denovoSkin(TM)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Regenerative medicine. Area: Dermatology.

phase 3 Regenerative medicine Dermatology Biologic Live · refreshed every 30 min

Target snapshot

denovoSkin(TM) (denovoSkin(TM)) — CUTISS AG. denovoSkin(TM) is a regenerative medicine treatment that uses a patient's own skin cells to repair damaged skin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
denovoSkin(TM) TARGET	denovoSkin(TM)	CUTISS AG	phase 3	Regenerative medicine
Leukocyte rich platelet rich plasma	Leukocyte rich platelet rich plasma	University Hospitals Cleveland Medical Center	marketed	Autologous cell therapy / Regenerative medicine product
Regenerative tissue matrix	Regenerative tissue matrix	University of Louisville	marketed	Regenerative medicine product / Tissue engineering scaffold
Platelet Rich Plasma (PRP)	Platelet Rich Plasma (PRP)	Aspetar	marketed	Autologous cell therapy / Regenerative medicine
AMNIOGEN	AMNIOGEN	Kaohsiung Veterans General Hospital.	marketed	Biological tissue product / Regenerative medicine
Reactivation Mismatch	Reactivation Mismatch	Massachusetts General Hospital	marketed	Regenerative medicine
Low-dose PRP	Low-dose PRP	Hospital for Special Surgery, New York	marketed	Autologous cell therapy / Regenerative medicine product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Regenerative medicine class)

Amarantus BioScience Holdings, Inc. · 1 drug in this class
CUTISS AG · 1 drug in this class
Massachusetts General Hospital · 1 drug in this class
zhang li · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). denovoSkin(TM) — Competitive Intelligence Brief. https://druglandscape.com/ci/denovoskin-tm. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing